Enacted in January 1966
Recently revised in March, 2019
Blood Research is a peer-reviewed open-access journal that delivers significant clinical, translational and basic study results in hematology and related fields to readers worldwide. Blood Research presents coverage on topics from basic laboratory research to clinical studies, translational studies, and precision medicine in the field of hematology.
Original Article is a manuscript containing results of clinical, laboratory, or experimental investigations. The article should be organized in the order of Title page, Abstract, Introduction, Materials and Methods, Discussion, Acknowledgments, References, Tables and Figures. Length is limited to 3500 words of body text and 30 references.
Review Article is usually solicited by the Editor-in-Chief. Authors who wish to submit an unsolicited review should contact the Editor-in- Chief. Topics of scientific consensus or remaining controversial may be dealt with in the review. It is organized as Title page, Abstract, Introduction, body text, Conclusion, Acknowledgments, References, Tables and Figures. Length is limited to 250 words of unstructured abstracts, 5000 words of body text, and 150 references.
Editorial is usually written by Editorial Board members. It focuses on the recent hot issues or deals with the articles in the corresponding issue. It may include up to 1200 words and 10 references.
Perspective article covers a wide variety of topics of current hematology- related issues. It may include up to 1200 words, one figure, 2 tables and 10 references.
Letter to the Editor that contains brief communications on interesting topics in hematology may be considered for publication. Comments that concern previously published articles may also be considered, and if necessary, responses by the author of the subject paper may be provided. Letters may be edited by the Editorial Board. The maximum length of a Letter is 1,500 words. Letters should have no more than 6 authors, 2 tables, 2 figures with legends, and 15 references.
Image of Hematology is intended to share an interesting and impressive hematology-related image that has not been submitted or published elsewhere. The title should contain no more than 10 words and the legend should contain no more than 200 words.
Manuscripts must be submitted online at https://www.bloodresearch.or.kr. Follow the instructions step by step. Authors, reviewers, and editors can send and receive all correspondences through this online system. All procedures after submission are informed to the first and corresponding authors. Any inquiries on the submitted manuscript may be asked to the Editorial Office via e-mail such as request of letter of acceptance for publication, request of change of authors, or other related requests. And authors who are unable to submit via online should contact the Editorial Office.
The Editorial Office of Blood Research
King's Garden Officetel 2-220, 24, Sajik-ro 8-gil, Jongno-gu, Seoul, Korea, 03174, Korea
Phone: +82-2-516-6581, Fax: +82-2-516-6582
Upon submitting a paper to Blood Research, authors are asked to declare their agreement to abide by the open access Creative Commons license 3.0. Contents of articles may be copied, distributed, and displayed without charge. Commercial use of the contents or their derivatives is also free of charge. However, the original authors must be given the credit for any reuse or distribution, and the license terms of the article must be made clear. Conditions of any kind can be waived if the authors give permission. For more information regarding the Open Access Agreement, please visit
Authorship: According to criteria formulated by the International Committee of Medical Journal Editors (ICMJE), authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet these 3 criteria. All other contributors who do not meet these criteria for authorship should be noted in the Acknowledgments section.
Conflict-of-Interest Statement: Authors must disclose any commercial or other associations that might pose a conflict of interest in connection with the submitted article. All funding sources supporting the work, and institutional or corporate affiliations of the authors, should be acknowledged in the title page.
Copyright: Authors should submit Copyright Transfer Agreement to the Editorial Office at the time of manuscript submission. This transfer will ensure the widest possible dissemination of information.
Registration of Clinical Trial Research: All clinical trials must be registered in a public registry prior to submission. The journal follows the trials registration policy of the ICMJE (http://www.icmje.org) and considers only trials that have been appropriately registered before submission.
Research and Publication Ethics: All human and animal studies must have been approved by the author's Institutional Review Board (IRB). Copies of written informed consents and IRB approval for clinical research should be kept. Clinical research should be done in accordance of the Ethical Principles for Medical Research Involving Human Subjects, outlined in the Declaration of Helsinki (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/). Clinical studies that do not meet the Declaration of Helsinki will not be considered for publication. Human subjects should not be identifiable, such that patients' names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.
Selection and description of participants clearly describe the selection of observational or experimental participants (healthy individuals or patients, including controls), including eligibility and exclusion criteria and a description of the source population. Because the relevance of such variables as age, sex, or ethnicity is not always known at the time of study design, researchers should aim for inclusion of representative populations into all study types and at a minimum provide descriptive data for these and other relevant demographic variables. Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants, the sex of animals or cells, and describe the methods used to determine sex and gender. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases (e.g., prostate cancer). Authors should define how they determined race or ethnicity and justify their relevance. Authors should use neutral, precise, and respectful language to describe study participants and avoid the use of terminology that might stigmatize participants.
Originality and Duplicate Publication: All submitted manuscripts should be original and should not be considered by other scientific journals for publication at the same time. Any part of the accepted manuscript should not be duplicated in any other scientific journal.
For the policies on research and publication ethics that are not stated in these instructions, the Good Publication Practice Guidelines for Medical Journals (https://www.kamje.or.kr) or the Guidelines on Good Publication Practice (http://publicationethics.org/files/u7141/1999pdf13.pdf) can be applied.
Reporting Guidelines for Specific Study Designs: It is recommended for authors to follow the reporting guidelines for the specific study design, such as randomized control study (ie, CONSORT), study of diagnostic accuracy (ie, STARD), meta-analyses and systematic reviews of randomized controlled trials (ie, PRISMA), meta-analyses and systematic reviews of observational studies (ie, MOOSE), and observational studies (ie, STROBE). The details are available on the website at http://www.icmje.org/icmje-recommendations.pdf.
After a manuscript is submitted, the Associate Editor of the relevant area reviews and sends the manuscript to two or more peer reviewers in the corresponding field. On the basis of the comments of the reviewers, the Associate Editor primarily determines whether the article is acceptable or not. A decision is made as "acceptance", "minor revision", "major revision" or "rejection. The author can check the status and the results of the review on the online system. After revising the manuscript, the author should upload the revised files with a reply to each item of the reviewers' opinion. Failure to resubmit the revised manuscript within 90 days is regarded as a withdrawal. Based on the opinion of the Associate Editor, the Editor-in-Chief will make a final decision on the approval for publication of the finally revised manuscripts and can request any further corrections or revisions if necessary. Statistical editing may be done if the data need professional statistical review by a statistician. The final revised manuscript should be submitted within 1 week of the request. If a manuscript is accepted for publication, the author will receive an acceptance letter by e-mail. The order of publication is the duty of the Editor-in-Chief. Any errors discovered in the articles after publication should be notified to the Editorial Office and be inserted in Erratum.
Similarity Check is a multipublisher initiative to screen published and submitted content for originality. To find out more about Similarity Check, visit https://www.crossref.org/services/similarity-check/. All manuscripts submitted to Blood Research are subject to screening using the iThenticate tool for textual similarity to other previously published works.
Notification of Acceptance
When an editor has decided that a manuscript is acceptable for publication, the corresponding author and the editorial office will be notified. The editorial office will check if the manuscript was prepared according to the guidelines although the authors are primarily responsible for formatting of the paper.
NO submission nor article publication charge.
Research frauds including forgeries, falsifications, plagiarisms, double publications, improper inclusion or exclusion of authors, etc. are strictly forbidden and will be dealt with guidelines set by the editorial board of Blood Research. The editor reserves the right to reject papers if ethical standards are not satisfactorily met.
Nisha Marwah, Manali Satiza, Niti Dalal, Sudhir Atri, Monika Gupta, Sunita Singh, Rajeev SenBlood Res 2021;56: 26-30
Junshik Hong, Seo-Yeon Ahn, Yoo Jin Lee, Ji Hyun Lee, Jung Woo Han, Kyoung Ha Kim, Ho-Young Yhim, Seung-Hyun Nam, Hee-Jin Kim, Jaewoo Song, Sung-Hyun Kim, Soo-Mee Bang, Jin Seok Kim, Yeung-Chul Mun, Sung Hwa Bae, Hyun Kyung Kim, Seongsoo Jang, Rojin Park, Hyoung Soo Choi, Inho Kim, Doyeun Oh; on behalf of the Korean Society of Hematology Thrombosis and Hemostasis Working PartyBlood Res 2021;56: 6-16
Yu Ri Kim, Dae-Young KimBlood Res 2021;56: S17-S25
Seyed Mohammad Sadegh Pezeshki, Najmadin Saki, Mehran Varnaseri Ghandali, Alireza Ekrami, Arshid Yousefi AvarvandBlood Res 2021;56: 38-43